StockNews.com began coverage on shares of MediciNova (NASDAQ:MNOV – Free Report) in a report published on Tuesday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.
MediciNova Price Performance
Shares of NASDAQ MNOV opened at $1.73 on Tuesday. The company has a market cap of $84.85 million, a PE ratio of -10.18 and a beta of 0.75. The company has a 50-day simple moving average of $1.74 and a 200-day simple moving average of $1.49. MediciNova has a 12 month low of $1.12 and a 12 month high of $2.16.
MediciNova (NASDAQ:MNOV – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01. On average, analysts anticipate that MediciNova will post -0.23 EPS for the current year.
About MediciNova
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
See Also
- Five stocks we like better than MediciNova
- How to Capture the Benefits of Dividend Increases
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- Trading Stocks: RSI and Why it’s Useful
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.